Displaying 3641 - 3660 of 4770
FTC Issues Interim Report on "Authorized Generic" Drugs
FTC Obtains $1.4 Million Civil Penalty for Premerger Filing Violations
FTC Chairman Leibowitz: Eliminating Pay-for-Delay Pharmaceutical Settlements Would Save Consumers $3.5 Billion Annually
Liberty Media Corporation and John C. Malone, United States of America (for the Federal Trade Commission)
John C. Malone, CEO and Chairman of Discovery Holding Company, agreed to pay a $1.4 million civil penalty to settle Federal Trade Commission charges that he violated the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in connection with acquisitions of Discovery shares in 2005 and 2008. The FTC alleged that Malone failed to file the required notice in 2005 after buying Discovery shares, and then in 2008 purchased additional Discovery shares before the expiration of a waiting period required by the HSR Act.
CSL Limited, a corporation, and Cerberus-Plasma Holdings, LLC, In the Matter of
The FTC authorized a lawsuit to block CSL Limited’s proposed $3.1 billion acquisition of Talecris Biotherapeutics Holdings Corporation, charging that the deal would would substantially reduce competition in the U.S. markets for four plasma-derivative protein therapies – Immune globulin (Ig), Albumin, Rho-D, and Alpha-1. These therapies are used to treat patients suffering from illnesses such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, alpha-1 antitrypsin disease, and hemolytic disease of the newborn. In approving the administrative complaint seeking to block the deal, the Commission also authorized the staff to seek a preliminary injunction in federal district court in Washington, D.C., to stop the transaction pending completion of the administrative trial. Following the FTC's lawsuit to block the transaction, CSL Limited announced that it would not proceed with its proposed acquisition.
FTC Testifies on "Competition Issues and Follow-on Biologic Drugs"
FTC Releases Report on Follow-on Biologic Drug Competition
Commission Grants, in Part, Petition of Hexion LLC and Huntsman Corporation to Reopen and Set Aside Orders
Chairman, Commissioners Issue Statement on Endocare, Inc.s Announcement That it has Terminated its Merger Agreement with Galil Medical Ltd.
Statement of the FTC's Bureau of Competition Regarding the Announcement that CSL Will Not Proceed with its Proposed Acquisition of Talecris Biotherapeutics
Hexion LLC, et al., In the Matter of
The FTC challenged Hexion LLC's proposed acquisition of Huntsman Corp., and settled its charges with a proposed consent order which requiredthe divestiture of Hexion's specialty epoxy business, and prevented the sharing of sensitive and non-public information which could lead to coordination of prices. Huntsman and Hexion are both producers of high-performance and specialty chemicals used in the aerospace and alternative energy industries. Subsequently, Hexion LLC and Huntsman Corporation petitioned the Commission to reopen and set aside two orders related to their proposed merger because they terminated their planned merger; the Commission granted, in part, the petition but left in place provisions of the order requiring Hexion for three years to seek the Commission’s approval prior to any acquisition of Huntsman, or any merger or other combination with Huntsman.
FTC Approves Final Consent Order Related to Reed Elsevier NV and ChoicePoint Inc.
Reed Elsevier NV, et al., In the Matter of
In September, 2008, the Commission challenged Reed Elsevier’s $4.1 billion proposed acquisition of ChoicePoint, which would have combined the two leading providers of electronic public record services provided to U.S. law enforcement customers. Public records services compile public and non-public records about individuals and businesses, including credit data, criminal, motor vehicle, property, and employment records, all used by law enforcement as an investigative tool in solving a wide variety of crimes. The transaction, as proposed, would have removed the intense rivalry that had lead to lower prices, product innovations, and improved services and support for law enforcement customers by eliminating the competition between Reed Elsevier’s LexisNexis product and ChoicePoint’s AutoTrackXP and CLEAR products. The Commission required divestiture of ChoicePoint’s product lines to Thomson Reuters Legal Inc. The Commission worked with the Attorneys General of eighteen states on this investigation.
FTC Settles Price-Fixing Charges Against San Francisco Bay Area Doctors Group
FTC Testifies in Support of Bill Banning Pay-for-Delay Settlements Between Brand and Generic Drug Companies
FTC Chairman Jon Leibowitz, Commissioner William E. Kovacic to Participate in Eighth Annual International Competition Network Conference in Zurich, Switzerland
FTC Authorizes Suit To Stop CSLs Proposed $3.1 Billion Acquisition of Talecris Biotherapeutics
FTC Approves Final Consent Order in Matter of BASF and Ciba Specialty Chemicals
Displaying 3641 - 3660 of 4770